Clinical Trials · NCT06864026
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
- Phase
- Phase 4
- Recruitment status
- Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 200
- Start date
- Mar 2025
- Locations
- 55 sites, United States, Puerto Rico
- Primary endpoint
- Percentage of Participants Achieving Normalized Functioning Health Assessment Questionnaire - Disability Index (HAQ-DI) ≤0.5 at 12 Months of Therapy